Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pharm |
RCV001787807 | SCV000925406 | drug response | nicotine response - Toxicity | 2021-03-24 | reviewed by expert panel | curation | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. |
OMIM | RCV000019049 | SCV000039336 | risk factor | Lung cancer susceptibility 2 | 2010-07-27 | no assertion criteria provided | literature only | |
OMIM | RCV000033213 | SCV000057060 | risk factor | Smoking as a quantitative trait locus 3 | 2010-07-27 | no assertion criteria provided | literature only | |
HLA Laboratory, |
RCV003234914 | SCV002819136 | uncertain significance | Susceptibility to severe coronavirus disease (COVID-19) due to high levels of fibrinogen and C-reactive protein | no assertion criteria provided | research |